Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abiomed, Inc. stock logo
ABMD
Abiomed
$381.02
$380.55
$219.85
$381.99
$17.18B1.4611,028 shs258 shs
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$168.58
0.0%
$179.58
$163.33
$251.99
$48.32B0.252.01 million shs5.09 million shs
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$73.79
-0.3%
$75.05
$58.93
$95.25
$43.40B1.125.24 million shs7.03 million shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$523.92
+0.8%
$486.81
$356.14
$530.73
$41.81B1.55650,255 shs1.05 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abiomed, Inc. stock logo
ABMD
Abiomed
0.00%0.00%0.00%0.00%0.00%
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
+0.02%-2.02%-2.70%-26.91%-27.88%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
-0.20%-1.77%-3.08%+4.73%-16.64%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
+0.78%+0.23%+4.60%+24.45%+4.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abiomed, Inc. stock logo
ABMD
Abiomed
1.4636 of 5 stars
0.00.00.04.30.61.71.9
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.9515 of 5 stars
4.24.03.34.03.22.51.3
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
4.5127 of 5 stars
2.25.00.04.02.52.52.5
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
3.8114 of 5 stars
1.45.00.03.73.12.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abiomed, Inc. stock logo
ABMD
Abiomed
0.00
N/AN/AN/A
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.36
Hold$219.2230.04% Upside
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
2.40
Hold$80.208.69% Upside
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2.78
Moderate Buy$546.004.21% Upside

Current Analyst Ratings Breakdown

Latest ABMD, BDX, EW, and IDXX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$515.00 ➝ $580.00
6/3/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$261.00 ➝ $241.00
6/2/2025
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
Dbs Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/22/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$217.00 ➝ $185.00
5/22/2025
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$84.00 ➝ $95.00
5/19/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$460.00 ➝ $510.00
5/13/2025
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$80.00 ➝ $83.00
5/6/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$280.00 ➝ $196.00
5/5/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$548.00 ➝ $558.00
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$280.00 ➝ $224.00
5/2/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$260.00 ➝ $185.00
(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abiomed, Inc. stock logo
ABMD
Abiomed
$1.03B16.65$5.09 per share74.88$33.03 per share11.54
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$20.87B2.32$21.12 per share7.98$89.57 per share1.88
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$5.44B7.96$2.72 per share27.09$17.06 per share4.33
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.93B10.72$12.53 per share41.82$19.48 per share26.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abiomed, Inc. stock logo
ABMD
Abiomed
$136.51M$5.8265.4769.783.3324.84%14.77%13.32%N/A
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.71B$5.2432.1710.781.277.28%15.99%7.36%8/7/2025 (Estimated)
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$4.17B$7.0010.5426.833.7375.48%16.62%12.64%7/23/2025 (Estimated)
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$887.87M$10.8248.4238.583.8022.76%57.35%26.97%8/5/2025 (Estimated)

Latest ABMD, BDX, EW, and IDXX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q2 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.28$3.35+$0.07$1.06$5.35 billion$5.27 billion
5/1/2025Q1 2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$2.93$2.96+$0.03$2.96$998.25 million$998.43 million
4/23/2025Q1 2025
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$0.60$0.64+$0.04$0.61$1.40 billion$1.41 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abiomed, Inc. stock logo
ABMD
Abiomed
N/AN/AN/AN/AN/A
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.162.47%N/A79.39%53 Years
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
N/AN/AN/AN/AN/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
N/AN/AN/AN/AN/A

Latest ABMD, BDX, EW, and IDXX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$1.042.02%6/9/20256/9/20256/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abiomed, Inc. stock logo
ABMD
Abiomed
N/A
7.93
7.17
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.70
1.13
0.64
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
0.06
4.45
3.66
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.31
1.16
0.81

Institutional Ownership

CompanyInstitutional Ownership
Abiomed, Inc. stock logo
ABMD
Abiomed
94.48%
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
79.46%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
87.84%

Insider Ownership

CompanyInsider Ownership
Abiomed, Inc. stock logo
ABMD
Abiomed
2.50%
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.36%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
1.29%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.98%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abiomed, Inc. stock logo
ABMD
Abiomed
2,00345.09 million43.96 millionOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
74,000286.61 million285.58 millionOptionable
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
15,800586.60 million579.03 millionOptionable
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
11,00080.42 million79.63 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abiomed stock logo

Abiomed NASDAQ:ABMD

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$168.58 -0.01 (-0.01%)
Closing price 06/20/2025 03:59 PM Eastern
Extended Trading
$168.44 -0.13 (-0.08%)
As of 06/20/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Edwards Lifesciences stock logo

Edwards Lifesciences NYSE:EW

$73.79 -0.19 (-0.26%)
Closing price 06/20/2025 03:59 PM Eastern
Extended Trading
$73.82 +0.04 (+0.05%)
As of 06/20/2025 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

IDEXX Laboratories stock logo

IDEXX Laboratories NASDAQ:IDXX

$523.92 +4.07 (+0.78%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$524.55 +0.63 (+0.12%)
As of 06/20/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.